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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of family-based interventions to improve outcomes in people with type 2 diabetes mellitus and to consider, where
possible, which components of the interventions are most effective.
B A C K G R O U N D
Description of the condition
Diabetes mellitus is a metabolic disorder resulting from a de-
fect in insulin secretion, insulin action, or both. Insulin defi-
ciency invariably leads to chronic hyperglycaemia (elevated levels
of plasma glucose), with disturbances of carbohydrates, fat, and
protein metabolism. There are different types of diabetes mellitus;
the most common are type 1 diabetes mellitus (T1DM) and type
2 diabetes mellitus (T2DM). Type 2 diabetes affects individuals
with relative insulin deficiency and insulin resistance. Insulin re-
sistance is characterized by failure of the body tissue to dispose
glucose in response to insulin due to excess body weight. Both
insulin deficiency and insulin resistance lead to hyperglycaemia
in T2DM. Although there are various causes of T2DM, these are
still not fully understood. Compared to T1DM, T2DM is often
associated with strong genetic risk. The risk of developing T2DM
increases with several factors such as age, obesity, lack of physical
activity, history of gestational diabetes, dyslipidaemia (abnormal
amount of lipids in the blood), and hypertension (ADA 2017).
The prevalence of diabetes is steadily increasing across the globe
(IDF 2015). The true global figures of the number of people
with diabetes are unknown, but the World Health Organization
(WHO) estimated in 2014 that 422 million people were affected
(WHO 2016), and the International Diabetes Federation (IDF)
estimated that there were 415 million cases in 2015 (IDF 2015),
excluding children. These estimates indicate an approximate dou-
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bling of the global prevalence (age-standardised) of diabetes from
1980, when there were 108 million cases (WHO 2016). The IDF
highlighted that diabetes had affected 9% of adults in 2015 (IDF
2015). The majority of these people (above 90%) have T2DM
(ADA 2017; King 1998). The IDF estimates that there will be 642
million people with diabetes in the world by 2040. This means
one in every 10 adults will have diabetes. This dramatic growth
of diabetic people places serious demands on healthcare services.
Health expenditure on diabetes is estimated to be USD 673 bil-
lion to USD 1197 billion annually, accounting for up to 12% of
overall global health expenditure in 2015 (IDF 2015). Globally,
the health expenditure for people with diabetes is two- to three-
fold higher than for people without diabetes (IDF 2015).
Diabetes leads to multiple complications that can increase the
overall risk of early death. People with T2DM suffer from com-
plications such as microvascular and macrovascular complications
as a result of sub-optimal control of blood glucose (ADA 2017;
WHO 2016). The development of microvascular complications
increases with both the severity and duration of hyperglycaemia,
while the risk of macrovascular complications depends on age,
gender, genetic factors, and behaviour (e.g. exercise, diet, smoking)
(Vermeire 2005). Microvascular complications include retinopa-
thy (retina damage), nephropathy (kidney damage), and neuropa-
thy (nerve damage). The principal mechanism of macrovascular
complications is atherosclerosis (narrowing of arteries due to the
build up of plaque), which results from chronic inflammation and
injury to the arterial wall in the peripheral or coronary vascular
system. This leads to narrowing of arterial walls, which can con-
sequently lead to cerebrovascular diseases (e.g. stroke, transient is-
chemics attack) (ADA 2017; Fowler 2008; WHO 2016). In peo-
ple with T2DM, prospective trials have demonstrated an associa-
tion between the degree of hyperglycaemia and the increased risk
of microvascular and macrovascular complications, and all-cause
mortality (Stratton 2000).
Several trials in T2DM have indicated that the incidence of com-
plications can be improved by metabolic control achieved through
a combination of behaviour-changing interventions or pharma-
cological management, or both (Ohkubo 1995; UKPDS 1998).
Therefore, reducing the risk of complications requires continu-
ous medical care and multifaceted risk reduction strategies. Be-
haviour-changing interventions involve diabetes self-management
education (DSME), diabetes self-management support (DSMS),
physical activity, nutrition therapy (ADA 2017; Ohkubo 1995;
UKPDS 1998), psychosocial care, smoking cessation (ADA 2017),
and medication management (Deakin 2005; IDF 2015). Adher-
ence to a diabetes treatment recommendations has been associated
with improved outcomes (Sabate 2003; UKPDS 1998; Watkins
2003). Improving glycaemic control in individuals with T2DM
reduces the incidence of microvascular complications (Stratton
2000); whether the same is true about macrovascular complica-
tions remains uncertain (Stratton 2000)
Description of the intervention
Disease management can be complex for people with diabetes and
their families (ADA 2017; WHO 2016). Family-based interven-
tions include supporting family members in caring for patients
with chronic illnesses, because disease management mostly takes
place within homes and communities (Baig 2015; Fisher 2000).
Family members include people who have legal, biological, or
emotional relationships with the patient (Baig 2015). Key compo-
nents of family support may include training family members in
supportive communication, providing family members with the
necessary tools that assist in monitoring clinical symptoms, and
guiding family members to set goals for self-care behaviour (Baig
2015). Family members play direct and indirect roles in disease
management (Deakin 2005). Disease management affects family
members behaviorally (Rosland 2012), cognitively, and emotion-
ally (Fisher 1998; Fisher 2000). Family-based interventions do not
occur in an isolated social context, but rather as an adjunct to usual
treatment (Armour 2005; Fisher 2000).
Approaches for supporting people with T2DM to modify and
sustain behaviours involve a mix of health service change, edu-
cation, behavioural interventions, and psychosocial interventions
(Thorpe 2013). These interventions have tended to focus on in-
dividuals, rather than their families and social environments (Baig
2015; Fisher 2000). Family approaches emphasise addressing ed-
ucational, relational, and personal needs of both the individual
and family members (Armour 2005; Fisher 2000). Unlike usual
care, family-based interventions are concerned with the psychoso-
cial and emotional aspects of diseases. This may explain why peo-
ple with diabetes are less likely to adhere to behaviour-changing
modifications without intervention (Deakin 2005). Thus, family
approaches to chronic disease management may be promising in
complementing traditional treatment strategies (Fisher 1998).
Adverse effects of the intervention
Family relationships can either be protective or a risk factor
(Mayberry 2012). Family members can have positive or negative
impacts on the health of people with diabetes. For example, fam-
ily members can facilitate or interfere with self-care activities such
as refilling prescriptions or buying groceries (Mayberry 2012).
Therefore, recognising which specific family behaviours are linked
to better or worse disease management could enable better under-
standing and inform strategies that families could use to increase
their effective support (Rosland 2012).
How the intervention might work
Several conceptual frameworks and theoretical models describe
the mechanisms by which family-based interventions influence
the outcomes of chronic diseases. Logically, family-based inter-
ventions provide an arena where the individual, family members
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and healthcare systems intersect. This intersection might provide
an ideal environment for meaningful intervention in an appro-
priate context (Baig 2015). A 2013 systematic review on the role
of family in adults with diabetes reported that most interven-
tion studies were based on relatively similar hypotheses (Torenholt
2014). Reviewed intervention studies hypothesise that active fam-
ily involvement could improve social support (Armour 2005; Baig
2015; Rosland 2012; Torenholt 2014), which can in turn facil-
itate adopting and maintaining diabetes self-management skills
(Armour 2005). Disease outcomes might be improved as a re-
sult. Theoretically, family-based intervention studies outline cer-
tain models based on the social dimensions. For instance, family
system theory describes the influence of emotional interconnect-
edness on family members’ approaches to disease management.
Likewise, interdependence theory appreciates that interaction af-
fects both the family and the individual (Rosland 2012; Torenholt
2014).
Key findings suggest two principal mechanisms by which family
relationships can influence outcomes in chronic diseases, i.e. family
dynamics and social context (Fisher 1998; Fisher 2000).
• Family dynamics are thought to influence outcomes in
chronic diseases (Torenholt 2014), due to the vital interaction
among three factors. This vital interaction tends to produce
lively association between the three principal factors. These
factors are: the family’s developmental stage (i.e. family’s coping
skills and conflicts resolution, taking into account social and
economic status) (Fisher 1998; Wens 2005); family
characteristics (e.g. family organisation, beliefs, emotions, and
problem solving skills); and characteristics of diseases (e.g.
chronicity, demands for care, typical course) (Fisher 1998).
Characteristics of family relationships (e.g. cohesion, stability,
family satisfaction, and interpersonal criticalness) can have
enhancing or disruptive effects on disease outcomes (Baig 2015;
Fisher 1998). For instance, responses from family members to
the disease and its management can impact peoples’ self-
management behaviours (Fisher 2000).
• The family social context of disease management is
potentially central to successful adaptation of self-regulation
skills (Fisher 1998; Fisher 2000). Family social context includes
physical, psychosocial, relational, familial, educational, and
personal needs and interests of both the family and the
individual. In the case of diabetes, most of the self-regulatory
behaviours involved in the self-management of the condition
occur in the home environment, and can be therefore be
influenced by family members (Fisher 2000). This is particularly
true in certain cultures where family is still intact and cohesive
(Baig 2015). Fisher and colleagues argue that family social
context is the greatest, most pervasive, with the longest lasting
influence on the management of T2DM (Fisher 1998).
Adopting behavioural self-regulation skills such as taking
medication, testing glucose, and modifying diet require a
receptive family social context (Fisher 1998; White 2005).
One of the key challenges of disease management for diabetes
is that people with diabetes may not perceive many of the be-
haviour changing modifications required (such as dietary restric-
tions and exercise) as desirable. This can negatively affect ad-
herence (Armour 2005; Davies 2008; Gonder-Frederick 2002;
Keogh 2011). Within the family-based intervention, family and
disease outcomes seem to result primarily by the reciprocal deter-
minism between family dynamics and social context (Baig 2015;
Fisher 1998; White 2005). In reciprocal determinism a person’s
behaviour both influences and is influenced by personal factors
and the social environment (Bandura 1978). This reciprocal asso-
ciation, in turn, can lead to a greater sense of well-being, improved
diabetes self-management behaviours (Torenholt 2014), and po-
tentially improved disease outcomes (Armour 2005; Fisher 2000;
Rosland 2012; Torenholt 2014; White 2005). A recent systematic
review targeting diabetes outcomes through family-based inter-
ventions among adults with diabetes, found evidence for improve-
ment in diabetes-related self-care, diabetes knowledge, perceived
social support and self-efficacy (Baig 2015).
Why it is important to do this review
Although some evidence indicates that family-based interventions
are potentially valuable in improving diabetes outcomes (Baig
2015; Fisher 1998; Torenholt 2014), research targeting the in-
terface between adults with chronic diseases and their families
is relatively scarce (Torenholt 2014). Despite the wide use of
family-based interventions in managing diabetes among children
(Armour 2005; Baig 2015 Chesla 2010; Hood 2010), the existing
literature suggests their use is limited among adults (Baig 2015;
Thorpe 2013; Torenholt 2014), particularly among people with
T2DM (Gonder-Frederick 2002; White 2005; White 2007). Al-
though various interventions to improve T2DM outcomes have
been developed over the past twenty years (Steed 2003), research
on family interventions for chronic diseases remains developmen-
tal (Torenholt 2014). Therefore, a comprehensive assessment of
the published literature is necessary to assess the effectiveness of
family-based intervention in people with T2DM, and to consider
where possible which components of the intervention are effec-
tive.
A previous systematic review of randomised controlled trials
(RCTs) examined the effectiveness of family-based interventions
designed to improve outcomes in people with diabetes (Armour
2005). The review was limited in that it included only published
trials which used randomised trial designs where family mem-
bers were residing together. A recent systematic review included
all study types (e.g. RCTs, pre-post, pilot) and examined family-
based interventions for adults with diabetes (Baig 2015). Limita-
tions of that review were that it included only published studies
in English or Spanish, and only studies that were conducted in
the United States (Baig 2015). Our proposed review intends to
overcome these limitations by: 1) including RCTs and controlled
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clinical trial (CCT) designs; 2) including trials of interventions
delivered to affected individuals and family members not neces-
sarily residing together; and 3) including trials published in all
languages, with no geographical limitations.
O B J E C T I V E S
To assess the effects of family-based interventions to improve out-
comes in people with type 2 diabetes mellitus and to consider,
where possible, which components of the interventions are most
effective.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled trials (RCTs) and con-
trolled clinical trials (CCTs).
Types of participants
Family members will be adults (aged 18 years or more), and will
include any relative in regular contact with the person with type
2 diabetes mellitus (T2DM) and who is significantly involved in
supporting the person in the management of their illness. The
family member for this review is not necessarily a carer, but some-
one with whom the person with T2DM has a close relationship.
This may include: parent; grandparent; child; grandchild; sibling;
aunts; uncles; nieces; nephews; step-parent, or stepchild.
Diagnostic criteria for diabetes mellitus
To be consistent with changes in the classification of and diagnostic
criteria for diabetes mellitus over the years, the diagnosis should be
established using the standard criteria valid at the time of the trial
commencing (for example: ADA 2003; ADA 2017; WHO 1999).
Ideally, the diagnostic criteria should have been described. We will
use the trial authors’ definition of diabetes mellitus if necessary.
We plan to conduct a sensitivity analysis according to diagnostic
criteria used.
Changes in diagnostic criteria may produce significant variability
in the clinical characteristics of the participants included, as well
as in the results obtained (which we will also investigate through
subgroup analysis).
Types of interventions
We plan to investigate family-based interventions in comparison
with a control group. As there is no standard definition for “fam-
ily-based intervention”, for this review we will define these as any
interventions designed to improve outcomes in adults (above 18
years) with T2DM, which involve at least one other family mem-
ber, and are delivered in a community or ambulatory care setting
(e.g. home-based). Trials involving interventions delivered to a
family member alone will only be included if they assess outcomes
for the person with diabetes.
Intervention
• Family-based intervention
Comparator
• Usual care
We will define the control group as having usual care in the setting
of T2DM (e.g. team care, specialist care, family physician care,
or any other model of care). As there will be differences to what
constitutes usual care, we will clearly describe this for all trials
included in the review.
Concomitant interventions must be the same in both the inter-
vention and comparator groups to establish fair comparisons. If a
trial includes multiple arms, we will include any arm that meets
our inclusion criteria.
Minimum duration of intervention
The minimum duration of intervention will be four weeks.
Minimum duration of follow-up
The minimum duration of follow-up will be three months.
Summary of specific exclusion criteria
We will exclude trials:
• that do not include an appropriate comparison group;
• that do not assess outcomes for individuals with T2DM
(i.e. they asses outcomes for family members alone);
• where family interventions are delivered only to individuals
with T2DM (i.e. not their family members);
• that are targeted to family interventions for individuals with
type 1 diabetes mellitus; or
• where family interventions are delivered to individuals with
T2DM who are less than 18 years of age.
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Types of outcome measures
We will not exclude any trial on the basis that it does not report one
or several of our primary or secondary outcome measures in the
publication. Should none of our primary or secondary outcomes
be reported in a trial, we will not include the trial but will provide
some basic information in an additional table.
We will investigate the following outcomes using the methods and
time points specified below.
Primary outcomes
• Glycaemic control
• Diabetic complications
• Adverse evens
Secondary outcomes
• All-cause mortality
• Health-related quality of life
• Social support
• Health behaviour
• Diabetes knowledge
• Socioeconomic effects
Method of outcome measurement
• Glycaemic control: measured by glycosylated haemoglobin
A1C (HbA1c).
• Diabetic complications: defined as angina pectoris,
myocardial infarction, stroke, peripheral vascular disease,
neuropathy, nephropathy, retinopathy, diabetic foot and lower
limb amputation, and heart failure, measured in the long term.
• Adverse events: such as family non-supportive behaviours
(e.g. sabotaging behaviours, and miscarried helping behaviours.
Sabotaging behaviours occur when family members are well-
informed about diabetes but do not help participants to perform
diabetes self-care behaviours. For example, disrupting diabetic
participant’s attempt to change eating habits. Miscarried
behaviours happen when family members attempt to help with
diabetes self-care, but do so in an inadequate or incorrect
manner. For instance, couples experience conflicts when a
husband attempts to modify the wife’s diet, but the wife does not
appreciate husband’s attempt to do so).
• All-cause mortality: defined as death from any cause.
• Health-related quality of life: evaluated with a validated
generic or disease-specific instrument (e.g. Audit of Diabetes-
Dependent Quality of Life (ADDQoL) (Wee 2006), 36-Item
Short Form Health Survey (SF-36) (McHorney 1993).
• Social support: defined as emotional or practical support,
and measured using a validated instrument (e.g. Short-form
Social Support Questionnaire (SSQ-6) (Sarason 1983), or any
other validated scale).
• Health behaviour: defined as self-care behaviours, evaluated
with a validated instrument (e.g. Summary of Diabetes Self-care
Activities measure (Toobert 2000), or any other validated scale).
• Diabetes knowledge: evaluated with validated instrument
(e.g. Diabetes Knowledge Questionnaire (Garcia 2001), or any
other validated scale).
• Socioeconomic effects: defined as the costs of treatment and
visits to clinic or hospital, such as hospital admissions, accident
and emergency visits, length of stay in hospital, or visits to
general practitioner.
Timing of outcome measurement
• We will include outcomes that are measured for as long as
follow-up is carried out at any given time point. We will classify
the outcome measurement as short-, medium-, or long-term. We
will define short-term as less than six months; medium-term as
between six months and less than 12 months; and long-term as
12 months or more.
• HbA1c should be measured at least three months after the
intervention.
• We will measure adverse events and all-cause mortality at
any time after participants were randomised to intervention or
comparator groups.
Search methods for identification of studies
Electronic searches
We will search the following sources from the inception of each
database to the specified date, and will place no restrictions on the
language of publication.
• Cochrane Central Register of Controlled Trials
(CENTRAL) via the Cochrane Register of Studies Online
(CRSO);
• MEDLINE Ovid (Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE Daily and
Ovid MEDLINE; from 1946 onwards);
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature);
• PsycINFO Ovid;
• ClinicalTrials.gov (www.clinicaltrials.gov);
• World Health Organization International Clinical Trials
Registry Platform ( ICTRP) ( www.who.int/trialsearch/).
We will continuously apply a MEDLINE (via Ovid SP) email
alert service established by the Cochrane Metabolic and Endocrine
Disorders (CMED) Group to identify newly published trials, using
the same search strategy as described for MEDLINE (Appendix
1). After we submit the final review draft for editorial approval,
the CMED Group will perform a complete search update on all
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databases available at the editorial office and will send the results
to the review authors. Should we identify new trials for inclusion,
we will evaluate these, incorporate the findings into our review
and resubmit another Cochrane Review draft (Beller 2013).
Searching other resources
We will try to identify other potentially eligible trials or ancillary
publications by searching the reference lists of included trials, sys-
tematic reviews, meta-analyses and health technology assessment
reports. In addition, we will contact authors of included trials to
identify any additional information on the retrieved trials and es-
tablish whether we may have missed further trials.
We will not use abstracts or conference proceedings for data ex-
traction unless full data are available from trial authors because this
information source does not fulfil the CONSORT requirements
which consist of “an evidence-based, minimum set of recommen-
dations for reporting randomised trials” (CONSORT; Scherer
2007). We will list key data from abstracts in an appendix. We will
present information on abstracts or conference proceedings in the
’Characteristics of studies awaiting classification’ table.
Data collection and analysis
Selection of studies
Two review authors (KM, SD) will independently screen the ab-
stract, title, or both, of every record we retrieve in the literature
searches, to determine which trials we should assess further. We
will obtain the full text of all potentially relevant records. We will
resolve any disagreements through consensus or by recourse to a
third review author (SC). If we cannot resolve a disagreement,
we will categorise the trial as a ’study awaiting classification’ and
will contact the trial authors for clarification. We will present an
adapted PRISMA flow diagram to show the process of trial selec-
tion (Liberati 2009). We will list all articles excluded after full-text
assessment in a ’Characteristics of excluded studies’ table and will
provide the reasons for exclusion.
Data extraction and management
For trials that fulfil our inclusion criteria, two review authors (KM,
SD) will independently extract key participant and intervention
characteristics. We will describe interventions according to the
’template for intervention description and replication’ (TIDieR)
checklist (Hoffmann 2014; Hoffmann 2017).
We will report data on efficacy outcomes and adverse events using
standardised data extraction sheets from the Cochrane Metabolic
and Endocrine Disorders Group. We will resolve any disagree-
ments by discussion or, if required, we will consult a third review
author (SC).
We will provide information about potentially relevant ongoing
trials, including the trial identifiers, in the ’Characteristics of ongo-
ing studies’ table and in a joint appendix, ’Matrix of trial endpoint
(publications and trial documents)’. We will try to find the proto-
col for each included trial and we will report primary, secondary
and other outcomes in comparison with data in publications in a
joint appendix.
We will email all authors of included trials to enquire whether
they would be willing to answer questions regarding their trials.
We will present the results of this survey in an appendix. We will
thereafter seek relevant missing information on the trial from the
primary trial author(s), if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we will maximise the informa-
tion yield by collating all available data, and we will use the most
complete data set aggregated across all known publications. We
will list duplicate publications, companion documents, multiple
reports of a primary trial, and trial documents of included trials
(such as trial registry information) as secondary references under
the study ID of the included trial. Furthermore, we will also list
duplicate publications, companion documents, multiple reports
of a trial, and trial documents of excluded trials (such as trial reg-
istry information) as secondary references under the study ID of
the excluded trial.
Data from clinical trials registers
If data from included trials are available as study results in clinical
trials registers, such as ClinicalTrials.gov or similar sources, we
will make full use of this information and extract the data. If
there is also a full publication of the trial, we will collate and
critically appraise all available data. If an included trial is marked
as a completed study in a clinical trial register but no additional
information (study results, publication or both) is available, we
will add this trial to the table ’Characteristics of studies awaiting
classification’.
Assessment of risk of bias in included studies
Two review authors (KM, SD) will independently assess the ’Risk
of bias’ of each included trial. We will resolve any disagreements
by consensus or by consulting a third review author (SC). In the
case of disagreement, we will consult the remainder of the review
author team and make a judgment based on consensus. If adequate
information is not available from the publications, trial protocols
or other sources, we will contact the trial authors for more detail
to request missing data on ’Risk of bias’ items.
We will use the Cochrane ’Risk of bias’ assessment tool (Higgins
2011a; Higgins 2017) to assign assessments of low, high or unclear
risk of bias (for details see Appendix 2). We will evaluate individual
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bias items as described in the Cochrane Handbook for Systematic
Reviews of Interventions according to the criteria and associated
categorisations contained therein(Higgins 2017).
Summary assessment of risk of bias
We will present a ’Risk of bias’ graph and a ’Risk of bias’ summary
figure.
We will distinguish between self-reported and investigator-assessed
and adjudicated outcome measures.
We will consider the following self-reported outcomes.
• Diabetes knowledge
• Health behaviour
• Health-related quality of life
• Social support
We will consider the following outcomes to be investigator-as-
sessed.
• Adverse events
• All-cause mortality
• Diabetic complications
• HbA1c
• Socioeconomic effects
Risk of bias for a trial across outcomes: some ’Risk of bias’
domains, such as selection bias (sequence generation and allocation
sequence concealment), affect the risk of bias across all outcome
measures in a trial. In case of high risk of selection bias, we will
mark all endpoints investigated in the associated trial as being
at high risk of bias. Otherwise, we will not perform a summary
assessment of the risk of bias across all outcomes for a trial.
Risk of bias for an outcome within a trial and across domains:
we will assess the risk of bias for an outcome measure by including
all entries relevant to that outcome (i.e. both trial-level entries and
outcome-specific entries). We consider low risk of bias to denote
a low risk of bias for all key domains, unclear risk to denote an
unclear risk of bias for one or more key domains, and high risk to
denote a high risk of bias for one or more key domains.
Risk of bias for an outcome across trials and across domains:
these are the main summary assessments that we will incorporate
into our judgements about the quality of evidence in the ’Summary
of findings’ tables. We will define outcomes as being at low risk of
bias when most information comes from trials at low risk of bias,
unclear risk when most information comes from trials at low or
unclear risk of bias and high risk when a sufficient proportion of
information comes from trials at high risk of bias.
Measures of treatment effect
When at least two included trials are available for a comparison
and a given outcome, we will try to express dichotomous data as a
risk ratio (RR) or odds ratio (OR) with 95% confidence intervals
(CIs). For continuous outcomes measured on the same scale (e.g.
HbA1c) we will estimate the intervention effect using the mean
difference (MD) with 95% CIs. For continuous outcomes that
measure the same underlying concept (e.g. health-related quality
of life) but use different measurement scales, we will calculate the
standardised mean difference (SMD). We will express time-to-
event data as a hazard ratio (HR) with 95% CIs.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, such as cross-over trials, cluster-randomised controlled tri-
als (RCTs), and multiple observations for the same outcome. If
more than one comparison from the same trial is eligible for in-
clusion in the same meta-analysis, we will either combine groups
to create a single pair-wise comparison or appropriately reduce the
sample size so that the same participants do not contribute data to
the meta-analysis more than once (i.e. splitting the ’shared’ group
into two or more groups). While the latter approach offers some
solution to adjusting the precision of the comparison, it does not
account for correlation arising from the same set of participants
being in multiple comparisons (Higgins 2011b).
We will attempt to re-analyse cluster-RCTs that have not appropri-
ately adjusted for potential clustering of participants within clus-
ters in their analyses. The variance of the intervention effects will
be inflated by a design effect. Calculation of a design effect in-
volves estimation of an intracluster correlation coefficient (ICC).
We will obtain estimates of ICCs through contact with authors,
or impute them by using either estimates from other included tri-
als that report ICCs or external estimates from empirical research
(e.g. Bell 2013). We plan to use sensitivity analyses to examine the
impact of clustering.
Dealing with missing data
If possible, we will obtain missing data from the authors of the in-
cluded trials. We will carefully evaluate important numerical data
such as screened, randomly assigned participants as well as inten-
tion-to-treat (ITT), and as-treated and per-protocol populations.
We will investigate attrition rates (e.g. dropouts, losses to follow-
up, withdrawals), and we will critically appraise issues concerning
missing data and use of imputation methods (e.g. last observation
carried forward).
In trials where the standard deviation (SD) of the outcome is not
available at follow-up or cannot be recreated, we will standardise
by the average of the pooled baseline SD from those trials that
reported this information.
Where included trials do not report means and SDs for outcomes
and we do not receive the necessary information from trial authors,
we will impute these values by estimating the mean and variance
from the median, range, and the size of the sample (Hozo 2005).
We will investigate the impact of imputation on meta-analyses by
performing sensitivity analyses and we will report per outcome
which trials were included with imputed SDs.
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Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we will not report trial results as the pooled effect estimate in
a meta-analysis.
We will identify heterogeneity (inconsistency) by visually inspect-
ing the forest plots and by using a standard Chi² test with a signifi-
cance level of α = 0.1. In view of the low power of this test, we will
also consider the I² statistic, which quantifies inconsistency across
trials to assess the impact of heterogeneity on the meta-analysis
(Higgins 2002; Higgins 2003).
When we identify heterogeneity, we will attempt to determine the
possible reasons for it by examining individual trial and subgroup
characteristics.
Assessment of reporting biases
We will use funnel plots to assess small-trial effects, as indicated by
the number of trials. Several explanations may account for funnel
plot asymmetry, including true heterogeneity of effect with respect
to trial size, poor methodological design (and hence bias of small
trials) and publication bias. Therefore we will interpret the results
carefully (Sterne 2011).
Data synthesis
We plan to undertake (or display) a meta-analysis only if we judge
participants, interventions, comparisons, and outcomes to be suf-
ficiently similar to ensure an answer that is clinically meaningful.
Unless good evidence shows homogeneous effects across trials of
different methodological quality, we will primarily summarise low
risk of bias data using a random-effects model (Wood 2008). We
will interpret random-effects meta-analyses with due considera-
tion to the whole distribution of effects and present a prediction
interval (Borenstein 2017a; Borenstein 2017b; Higgins 2009). A
prediction interval needs at least four trials to be calculated and
specifies a predicted range for the true treatment effect in an indi-
vidual trial (Riley 2011). For rare events such as event rates below
1%, we will use the Peto’s odds ratio method, provided that there
is no substantial imbalance between intervention and comparator
group sizes and intervention effects are not exceptionally large.
In addition, we will perform statistical analyses according to the
statistical guidelines presented in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Deeks 2011).
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity, and we plan to carry out the following subgroup anal-
yses including investigation of interactions (Altman 2003).
• Level of glycaemic control (e.g. HbA1c less than 8.5%
versus HbA1c 8.5% or more)
• Intervention duration (e.g. less than three months versus 3
months or more)
• Age (e.g. less than 65 years versus 65 years or more)
• Gender (e.g. male versus female individuals with T2DM)
Sensitivity analysis
We plan to perform sensitivity analyses to explore the influence of
the following factors (when applicable) on effect sizes by restricting
the analysis to:
• published trials;
• effect of risk of bias, as specified in the Assessment of risk of
bias in included studies section;
• very long or large trials (to establish the extent to which
they dominate the results);
• trials using the following filters: diagnostic criteria,
imputation, language of publication, source of funding (industry
versus other), or country.
We will also test the robustness of results by repeating the analyses
using different measures of effect size (RR, OR, etc.) and different
statistical models (fixed-effect and random-effects models).
Certainty of evidence
We will present the overall certainty of evidence for each outcome
specified below, according to the GRADE approach, which takes
into account issues related not only to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity, such as directness of results. Two review authors (KM,
SD) will independently rate the certainty of evidence for each
outcome. Differences in assessment will be solved by discussion
or consultation with a third researcher (SC).
We will include an appendix entitled ’Checklist to aid consistency
and reproducibility of GRADE assessments’, to help with stan-
dardisation of the ’Summary of findings’ tables (Meader 2014).
Alternatively, we will use the GRADEpro Guideline Development
Tool (GDT) software and will present evidence profile tables as an
appendix (GRADEproGDT 2015). We will present results for the
outcomes as described in the Types of outcome measures section.
If meta-analysis is not possible, we will present the results in a nar-
rative format in the ’Summary of findings’ table. We will justify all
decisions to downgrade the quality of trials using footnotes, and
we will make comments to aid the reader’s understanding of the
Cochrane Review where necessary.
’Summary of findings’ table
We will present a summary of the evidence in a ’Summary of find-
ings’ table. This will provide key information about the best esti-
mate of the magnitude of the effect, in relative terms and as abso-
lute differences, for each relevant comparison of alternative man-
agement strategies, numbers of participants and trials addressing
each important outcome and a rating of overall confidence in effect
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estimates for each outcome. We will create the ’Summary of find-
ings’ table based on the methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Schünemann 2011)
using Review Manager (RevMan 5.3) table editor (RevMan 2014).
We will report the following outcomes, listed according to prior-
ity.
• Diabetic complications
• Health-related quality of life
• Social support
• All-cause mortality
• Adverse events
• HbA1c
• Socioeconomic effects
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Appendix 1. Search strategies
MEDLINE (OvidSP)
1. exp Family/
2. Family Therapy/
3. Family Health/
4. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care giver?
or relatives) adj4 (therap* or based or focus* or educat* or management or support* or involv* or integrat* or participat* or counsel*)
).tw
5. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care giver?
or relatives) adj6 (intervention? or program*)).tw
6. or/1-5
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(Continued)
7. exp Diabetes Mellitus, Type 2/
8. (MODY or NIDDM or T2DM or T2D).tw.
9. diabet*.tw.
10. or/7-9
11. 6 and 10
[12-19: Cochrane Handbook 2008 RCT filter - sensitivity max. version - adapted for more sensitivity]
12. randomized controlled trial.pt.
13. controlled clinical trial.pt.
14. random*.ab.
15. placebo.ab.
16. drug therapy.fs.
17. trial.ab.
18. groups.ab.
19. or/12-18
20. exp animals/ not humans/
21. 19 not 20
22. 11 and 21
[23-28: Wong 2006a- systematic reviews filter - specificity max. version]
23. cochrane database of systematic reviews.jn.
24. search*.tw.
25. meta analysis.pt.
26. medline.tw.
27. systematic review.tw.
28. or/23-27
29. 11 and 28
30. 22 or 29
31. ((type 1 or type I) not (type 2 or type II)).ti,ab.
32. 30 not 31
33. (gestational diabetes or family history or case control or cross sectional or observational study).ti. or (case reports).pt
34. 32 not 33
Cochrane Central Register of Controlled Trials (Cochrane Register of Studies Online)
1. MESH DESCRIPTOR Family EXPLODE ALL TREES
2. MESH DESCRIPTOR Family Therapy
3. MESH DESCRIPTOR Family Health
4. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care
giver? or relatives) ADJ4 (therap* or based or focus* or educat* or management or support* or involv* or integrat* or participat* or
counsel*)):TI,AB,KY
5. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care giver?
or relatives) ADJ6 (intervention? or program*)):TI,AB,KY
6. #1 OR #2 OR #3 OR #4 OR #5
7. MESH DESCRIPTOR Diabetes Mellitus, Type 2 EXPLODE ALL TREES
8. (MODY or NIDDM or T2DM or T2D):TI,AB,KY
9. diabet*:TI,AB,KY
10. #7 OR #8 OR #9
11. #6 AND #10
PsycINFO (Ovid SP)
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(Continued)
1. Family/
2. exp Family Therapy/
3. Family Intervention/
4. Family Relations/
5. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care giver?
or relatives) adj4 (therap* or based or focus* or educat* or management or support* or involv* or integrat* or participat* or counsel*)
).tw
6. ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver? or care giver?
or relatives) adj6 (intervention? or program*)).tw
7. or/1-6
8. Type 2 Diabetes/
9. (MODY or NIDDM or T2DM or T2D).tw.
10. diabet*.tw.
11. or/8-10
12. 6 and 11
[13-16: Eady 2008“PsycInfo Search Strategies” filter - best sensitivity version]
13. control*.tw.
14. random*.tw.
15. exp Treatment/
16. or/13-15
17. 12 and 16
18. ((type 1 or type I) not (type 2 or type II)).ti,ab.
19. 17 not 18
20. (gestational diabetes or family history or case control or cross sectional or observational study or case report).ti
21. 19 not 20
22. book.pt.
23. 21 not 22
CINAHL (Ebsco)
S1. MH “Family+”
S2. MH “Family Therapy”
S3. MH “Family Coping”
S4. MH “Family Relations”
S5. MH “Family Services”
S6. MH “Patient-Family Relations”
S7. MH “Family Involvement (Iowa NIC)”
S8. MH “Family Support (Iowa NIC)”
S9. MH “Family Therapy (Iowa NIC)”
S10. TI ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver# or
care giver# or relatives) N4 (therap* or based or focus* or educat* or management or support* or involv* or integrat* or participat*
or counsel*))
S11. AB ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver# or
care giver# or relatives) N4 (therap* or based or focus* or educat* or management or support* or involv* or integrat* or participat*
or counsel*))
S12. TI ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver# or
care giver# or relatives) N6 (intervention# or program*))
S13. AB ((famil* or parent or parents or parental or marriage or marital or couple or couples or spouse or spouses or caregiver# or
care giver# or relatives) N6 (intervention# or program*))
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(Continued)
S14. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S15. MH “Diabetes Mellitus, Type 2”
S16. TI (MODY or NIDDM or T2DM or T2D)
S17. AB (MODY or NIDDM or T2DM or T2D)
S18. TI diabet*
S19. AB diabet*
S20. S15 OR S16 OR S17 OR S18 OR S19
[S21-S24: Wong 2006b“therapy studies” filter - SDSSGS version]
S21. MH “treatment outcomes+”
S22. MH “experimental studies+”
S23. random*
S24. S21 OR S22 OR S23
S25. S20 AND S24
S26. TI ((type 1 or type I) NOT (type 2 or type II))
S27. AB ((type 1 or type I) NOT (type 2 or type II))
S28. S26 OR S27
S29. S25 NOT S28
S30. TI (“gestational diabetes” OR “family history” OR “case control” OR “cross sectional” OR “observational study” OR “case
report”)
S31. S29 NOT S30
ICTRP (Standard search)
family based AND diabet* OR
family focus* AND diabet* OR
family oriented AND diabet* OR
family intervention AND diabet* OR
family therapy AND diabet* OR
family counseling AND diabet* OR
family based AND T2D* OR
family focus* AND T2D* OR
family oriented AND T2D* OR
family intervention AND T2D* OR
family therapy AND T2D* OR
family counseling AND T2D*
ClinicalTrials.gov (Advanced Search)
Conditions: (diabetes OR diabetic OR T2D OR T2DM ) AND NOT ( “type I” OR “type 1” OR gestational)
Intervention/treatment: (family or families OR spouse OR spouses OR marriage OR marital OR “couple” OR “couples” OR
caregiver OR “care giver” OR caregivers OR “care givers”) AND NOT (coupled OR coupling)
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Appendix 2. Selection bias decisions
Selection bias decisions for trials that reported unadjusted analyses: comparison of results obtained using method details
alone with results using method details and trial baseline informationa
Reported randomisation and
allocation concealment meth-
ods
Risk of bias judgement using
methods reporting
Information gained from
study characteristics data
Ris of bias using baseline in-
formation and methods re-
porting
Unclear methods Unclear risk Baseline imbalances present for
important prognostic variable
(s)
High risk
Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited or no baseline details Unclear risk
Would generate a truly random
sample, with robust allocation
concealment
Low risk Baseline imbalances present for
important prognostic variable
(s)
Unclear riskb
Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesc
Low risk
No baseline details Unclear risk
Sequence is not truly ran-
domised, or allocation conceal-
ment is inadequate
High risk Baseline imbalances present for
important prognostic variable
(s)
High risk
Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesc
Unclear risk
No baseline details High risk
aTaken from Corbett 2014; judgements highlighted in bold indicate situations in which the addition of baseline assessments would
change the judgement about risk of selection bias, compared with using methods reporting alone.
bImbalance identified that appears likely to be due to chance.
cDetails for the remaining important prognostic variables are not reported
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Appendix 3. Assessment of risk of bias
Risk of bias domains
Random sequence generation (selection bias due to inadequate generation of a randomised sequence)
For each included trial, we will describe the method used to generate the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups
• Low risk of bias: the trial authors achieved sequence generation using computer-generated random numbers or a random
numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if an independent
person performed this who was not otherwise involved in the trial. We will consider the use of the minimisation technique as
equivalent to being random.
• Unclear risk of bias: insufficient information about the sequence generation process.
• High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even
date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on
hospital or clinic record number; allocation by judgment of the clinician; allocation by preference of the participant; allocation
based on the results of a laboratory test or a series of tests; or allocation by availability of the intervention).
Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment)
We will describe for each included trial the method used to conceal allocation to interventions prior to assignment and we will assess
whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment
• Low risk of bias: central allocation (including telephone, interactive voice-recorder, web-based and pharmacy-controlled
randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
• Unclear risk of bias: insufficient information about the allocation concealment.
• High risk of bias: used an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without
appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.
We will also evaluate trial baseline data to incorporate assessment of baseline imbalance into the ’Risk of bias’ judgment for selection
bias (Corbett 2014). Chance imbalances may also affect judgments on the risk of attrition bias. In the case of unadjusted analyses,
we will distinguish between trials that we rate as being at low risk of bias on the basis of both randomisation methods and baseline
similarity, and trials that we judge as being at low risk of bias on the basis of baseline similarity alone (Corbett 2014). We will reclassify
judgements of unclear, low or high risk of selection bias as specified in Appendix 2.
Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants
and personnel during the trial)
We will evaluate the risk of detection bias separately for each outcome (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome measures (see below)
• Low risk of bias: blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have
been broken; no blinding or incomplete blinding, but we judge that the outcome is unlikely to have been influenced by lack of
blinding.
• Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial does not address
this outcome.
• High risk of bias: no blinding or incomplete blinding, and the outcome is likely to have been influenced by lack of blinding;
blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome is
likely to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment
We will evaluate the risk of detection bias separately for each outcome (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome measures (see below)
• Low risk of bias: blinding of outcome assessment is ensured, and it is unlikely that the blinding could have been broken; no
blinding of outcome assessment, but we judge that the outcome measurement is unlikely to have been influenced by lack of blinding.
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(Continued)
• Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome.
• High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to have been influenced by
lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome
measurement was likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias due to amount, nature or handling of incomplete outcome data)
For each included trial and/or each outcome, we will describe the completeness of data, including attrition and exclusions from the
analyses. We will state whether the trial reported attrition and exclusions, and report the number of participants included in the
analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We will also note
if the trial reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to
outcomes. We will consider the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or
disparate attrition rates (e.g. difference of 10% or more between trial arms)
• Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed
event risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data,
plausible effect size (mean difference or standardised mean difference) among missing outcomes was not enough to have a clinically
relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.
• Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle
missing data were likely to induce bias; the trial did not address this outcome.
• High risk of bias: reason for missing outcome data was likely to be related to true outcome, with either imbalance in numbers
or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically relevant bias in the intervention effect estimate; for continuous
outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes enough to induce
clinically-relevant bias in observed effect size; ’as-treated’ or similar analysis done with substantial departure of the intervention
received from that assigned at randomisation; potentially inappropriate application of simple imputation.
Selective reporting (reporting bias due to selective outcome reporting)
We will assess outcome reporting bias by integrating the results of the appendix ’Matrix of trial endpoints (publications and trial
documents)’ (Boutron 2014; Jones 2015; Mathieu 2009), with those of the appendix ’High risk of outcome reporting bias according
to the Outcome Reporting Bias In Trials (ORBIT) classification’ (Kirkham 2010). This analysis will form the basis for the judgement
of selective reporting
• Low risk of bias: the trial protocol was available and all the trial’s prespecified (primary and secondary) outcomes that were of
interest to this review were reported in the prespecified way; the study protocol was unavailable, but it was clear that the published
reports included all expected outcomes (ORBIT classification).
• Unclear risk of bias: insufficient information about selective reporting.
• High risk of bias: not all the trial’s prespecified primary outcomes were reported; one or more primary outcomes were reported
using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported
primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse
effect); one or more outcomes of interest in the Cochrane Review were reported incompletely so that we cannot enter them in a
meta-analysis; the trial report failed to include results for a key outcome that we would expect to have been reported for such a trial
(ORBIT classification).
Other bias
• Low risk of bias: the trial appears to be free from other sources of bias.
• Unclear risk of bias: there was insufficient information to assess whether an important risk of bias existed; insufficient rationale
or evidence that an identified problem introduced bias.
• High risk of bias: the trial had a potential source of bias related to the specific trial design used; the trial was claimed to be
fraudulent; or the trial had some other serious problem.
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N O T E S
We have based parts of the Methods, as well as Appendix 1, Appendix 2 and Appendix 3 of this Cochrane protocol on a standard
template established by the CMED Group.
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